Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10826562 | 0.89 | CA12 (0.45) | CYP2C19KMT2ASCN9AALDH1A1KDM4E | |
| SCHEMBL10826564 | 0.81 | ALDH1A1 (0.52) | SCN9AALDH1A1KDM4E | |
| SCHEMBL8920848 | 0.80 | CYP2C19 (0.47) | CYP2C19KMT2ASIGMAR1RAB9A | |
| SCHEMBL10827714 | 0.80 | NPC1 (0.59) | KMT2ARAB9AMEN1HSD17B10 | |
| SCHEMBL10826628 | 0.80 | NPC1 (0.42) | RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL9366810 | 0.80 | CYP2C19 (0.47) | CYP2C19KMT2ASIGMAR1RAB9A | |
| SCHEMBL12297902 | 0.78 | MEN1 (0.49) | KMT2AALDH1A1MEN1 | |
| SCHEMBL10826620 | 0.77 | ALDH1A1 (0.58) | KMT2ATDP1RAB9AALDH1A1KDM4E | |
| Phenylpiperazine SCHEMBL10826713 | 0.75 | HTR3E (0.44) | KMT2ASIGMAR1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL10827004 | 0.75 | TSHR (0.47) | CYP2C19KMT2ARAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4624963-A | Use of oxindole compounds for the treatment of epilepsy | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-11-25 | — | — | US | claimed |
| EP-3890833-B1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| US-20220047587-A1 | SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047548-A1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3891150-A1 | SYNERGISTIC COMPOSITIONS COMPRISING-R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2021-10-13 | — | — | EP | disclosed |
| EP-0401093-A1 | Pyrrolidone derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1990-12-05 | — | — | EP | disclosed |
| US-4624963-A | Use of oxindole compounds for the treatment of epilepsy | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-11-25 | — | — | US | disclosed |
| US-4614739-A | Oxindole derivatives, pharmaceutical compositions and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-30 | — | — | US | disclosed |
| US-4542151-A | CARDIOVASCULAR, BRONCHODILATION, ANALGESICS, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1985-09-17 | — | — | US | disclosed |
| US-4542148-A | 2-Oxo-3-phenyl indole derivatives, drugs having a neuroanabolic action containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | disclosed |
| EP-0062887-B1 | INDOLINONE-2 DERIVATIVES, PROCESS FOR THEIR PREPARATION AND NEURO-ANABOLIC MEDIUMS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0062887-A1 | Indolinone-2 derivatives, process for their preparation and neuro-anabolic mediums containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047587-A1 | SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO | CNR2, SCN2A, SIGMAR1 | CYP2C19 1316/4885KMT2A 4000/4885SIGMAR1 3/4885 |
| US-20220047548-A1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO | GAP43, CACNA1E, CACNA1D | CYP2C19 1115/4885KMT2A 4352/4885SIGMAR1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.